Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 5:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 7,392 matching trials from the live ClinicalTrials.gov search.
Conditions
Psoriasis, Plaque Psoriasis
Interventions
EDP1815, Placebo
Drug
Lead sponsor
Evelo Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Santa Rosa, California • Orlando, Florida • St. Petersburg, Florida + 5 more
Conditions
Diabetes Mellitus, Type 1
Interventions
Fast-acting insulin aspart, iLet™
Drug · Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Triple-Negative Breast Cancer
Interventions
Atezolizumab, Ipatasertib, Paclitaxel, Placebo for Atezolizumab, Placebo for Ipatasertib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
31
States / cities
Mobile, Alabama • Springdale, Arkansas • Los Angeles, California + 25 more
Conditions
Advanced Malignancies
Interventions
INCA32459-101
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Conditions
Colorectal Cancer, Liver Neoplasms
Interventions
NV1020
Drug
Lead sponsor
MediGene
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
San Diego, California • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
Conditions
Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia
Interventions
Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Tacrolimus
Drug · Procedure
Lead sponsor
Hannah Choe, MD
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Columbus, Ohio
Conditions
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
Interventions
VRx-3996 and valganciclovir
Combination Product
Lead sponsor
Viracta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
22
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 15 more
Conditions
Hodgkin Disease
Interventions
Nivolumab, Doxorubicin, Vinblastine, Dacarbazine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
14
States / cities
Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 8 more
Conditions
Alport Syndrome
Interventions
Placebo Oral Capsule, Bardoxolone Methyl
Drug
Lead sponsor
Biogen
Industry
Eligibility
12 Years to 60 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Postcoital Sponge on Self-Reported Vaginal Health Parameters

NCT06530186
Conditions
Vaginal Infection, Vaginal Discharge, Vaginosis, Sexual Dysfunction
Interventions
LiviWell Postcoital Vaginal Insert
Device
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Mountain Lakes, New Jersey
Conditions
Breast Neoplasms
Interventions
PD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more
Conditions
Lupus Nephritis (LN)
Interventions
C-CAR168
Biological
Lead sponsor
AbelZeta Inc.
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rockville, Maryland
Conditions
Brain Metastases
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Atumelnant in Healthy Participants

NCT07570082
Conditions
Healthy Volunteers
Interventions
Atumelnant, Carbamazepine, Midazolam, Digoxin, Metformin
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7, Thyroid Gland Anaplastic Carcinoma
Interventions
Laboratory Biomarker Analysis, Pazopanib Hydrochloride
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
16
States / cities
Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 13 more
Conditions
Heart Failure
Interventions
MouthLab Device
Other
Lead sponsor
WakeMed Health and Hospitals
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Raleigh, North Carolina
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
INCB000928, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 99 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Conditions
Breast Cancer
Interventions
Bevacizumab, Pictilisib, Letrozole, Paclitaxel, Trastuzumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Peoria, Illinois • Boston, Massachusetts • Nashville, Tennessee
Conditions
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma
Interventions
Docetaxel, Doxorubicin Hydrochloride, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Therapeutic Conventional Surgery
Drug · Radiation · Other + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Covid19
Interventions
hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
Biological · Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
El Segundo, California • Newport Beach, California
Conditions
High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma, Anaplastic Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
Interventions
LUTATHERA® (Lutetium Lu 177 dotatate)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
4 Years to 39 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
4
States / cities
Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio + 1 more
Conditions
Non Small Cell Lung Cancer
Interventions
STA 9090
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
21
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Duarte, California + 15 more
Conditions
Cachexia
Interventions
GSK2881078, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Baltimore, Maryland
Conditions
Non-Hodgkin's Lymphoma
Interventions
Obinutuzumab, Rituximab, Polatuzumab Vedotin, Venetoclax
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
10
States / cities
Tucson, Arizona • New Haven, Connecticut • Pembroke, Florida + 7 more